Alnylam Pharmaceuticals, Inc. drugs
4 results
Amvuttra (vutrisiran)
(VUTRISIRAN)Alnylam Pharmaceuticals, Inc.
Usage: AMVUTTRA is indicated for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, focusing on reducing cardiovascular mortality, hospitalizations, and urgent heart failure visits.
Givlaari (givosiran sodium)
(givosiran sodium)Alnylam Pharmaceuticals, Inc.
Usage: GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).
Onpattro (patisiran)
(patisiran)Alnylam Pharmaceuticals, Inc.
Usage: ONPATTRO is indicated for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.
Oxlumo (lumasiran)
(lumasiran)Alnylam Pharmaceuticals, Inc.
Usage: OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary and plasma oxalate levels in both pediatric and adult patients.